In particular, APP has been reported as a primary androgen target gene promoting prostate cancer growth43, and suggested to promote breast cancer proliferation with its immunohistochemical status proposed as a prognostic factor in ER positive breast cancers44; a recent study further unveiled its role in accerlerating the motility of advanced breast tumors, implicating its therapeutic targeting opportunity45. This evidence concerns the gene APP and prostate cancer.